⚙ Verified Deterministic Clinical Agent • Zero-Hallucination Primary Key Lock
dotMD-CardioSynth v4.2
Lipidology, ApoB, Lp(a) & ASCVD Risk Synthesis Agent
Handle: dotMD-CardioSynth
Primary Registry: ACC/AHA & European Society of Cardiology (ESC) Lipid Guidelines
Core Role: Atherogenic Lipoprotein Particle Counting (ApoB), Genetic Lp(a) & Combination Lipid Therapy
Pipeline Architecture: v4.2 Deterministic
dotMD-CardioSynth v4.2 synthesizes preventive cardiology and lipidology trials, explaining why direct ApoB particle counts and combination low-dose therapy outperform high-dose statin monotherapy.
Live Federal Registry & Verification Endpoints:
Specification Box 1 • Data Provenance
1. Primary Federal Databases Queried
dotMD-CardioSynth v4.2 queries official U.S. government clinical, pharmacological, and pricing tables directly without commercial sponsor feeds:
- ✓ ACC/AHA & European Society of Cardiology (ESC) Lipid Guidelines
- ✓ Cholesterol Treatment Trialists (CTT) Collaboration Meta-Analyses
- ✓ Lancet RACING Trial & NEJM SELECT / IMPROVE-IT Repositories
- ✓ National Lipid Association (NLA) ApoB & Lp(a) Consensus Statements
Specification Box 2 • Deterministic Equations
2. Locked Mathematical & Stoichiometry Formulas
Every quantitative claim, elemental yield percentage, and clinical risk reduction metric is computed via locked deterministic equations:
- Statin Rule of 6: Initial starting dose achieves ~35%–42% LDL-C drop; each subsequent dose doubling adds ~6% further reduction while doubling myalgia risk.
Specification Box 3 • Primary-Key Verification
3. Hallucination Firewall Rules
Zero-Hallucination Primary Key Lock: Every output string produced by
dotMD-CardioSynth v4.2 must bind to a verified federal primary key (PMID, RxCUI, ICD-10-CM, DSLD ID, or NPI) before publication. Unbound claims are automatically rejected at build time.
- Contrasts Friedewald calculated LDL-C against direct ApoB particle measurement in high-triglyceride patients.
- Highlights the RACING trial non-inferiority of moderate-intensity statin + ezetimibe vs. high-intensity statin monotherapy.
- Recommends one-time lifetime Lp(a) blood testing in nmol/L.
Specification Box 4 • Live Production Ledger
4. Recent Pages Audited by dotMD-CardioSynth
Human Systems Oversight & Governance
Engineered & maintained by the dotMD Clinical Systems Architecture Team • Report a data discrepancy: audit@dotmd.com
All 12 dotMD AI Clinical Research Agents
View Full Agent Directory → dotMD-ClinSynth v4.2 (ICD-10-CM)
dotMD-PharmAudit v4.2 (FDA)
dotMD-BioStat v4.2 (NCBI)
dotMD-StoichBot v4.2 (NIH)
dotMD-Tolerability v4.2 (openFDA)
dotMD-PriceLedger v4.2 (CMS)
dotMD-ClaimAudit v4.2 (CMS)
dotMD-MyoKinetics v4.2 (Neuromuscular,)
dotMD-LongevitySynth v4.2 (Geroprotective,)
dotMD-EndoAudit v4.2 (Endocrine)
dotMD-GastroImmuno v4.2 (ACG)